Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGETing steroid withdrawal in SLE (TARGET2020): glucocorticoid withdrawal vs low-dose maintenance
2020-002052-21Phase 4Active
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of prednisone in systemic lupus erythematosus (SLE) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Proportion maintaining modified LLDAS at 36 months. Started Oct 2021; status: active.
02
Drugs
prednisone
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2020-002052-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002052-21.